Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments
Tortorella Lucia1, Vizzielli Giuseppe1, Fusco Domenico2, Cho William C.3, Bernabei Roberto2, Scambia Giovanni1, Colloca Giuseppe2,*
1Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy. 2Geriartic Department, Fondazione Policlinico A.Gemelli, Rome, Italy 3Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
Ovarian cancer is the most common cause of death from gynecological cancers in developed countries. It is a common disease of older women at or above 63 years upon diagnosis. Thanks to advance in new treatments, mortality from ovarian cancer has declined in developed countries in the last decade. This decline in mortality rate is unevenly distributed across the age-spectrum. While mortality in younger women has decreased 21.7%, for elderly women it has declined only 2.2%. Even if ovarian cancer is clearly a disease of the elderly, older women are underrepresented in clinical trials, and scant evidence exists for the treatment of women older than 80 years. Moreover, older women are frequently undertreated, receive less chemotherapy and less combination of surgery and chemotherapy, despite the fact that this is considered the optimal treatment modality. This may be mainly due to the lack of evidence and physician’s confidence in the management of elderly women with ovarian cancer. In this review, we focus on the management of older women with ovarian cancer, considering geriatric features tied to this population.
Dumas L, Ring A, Butler J, Kalsi T, Harari D, Banerjee S. (2016). Improving outcomes for older women with gynecological malignancies. Cancer Treat Rev, 29: 50: 99-108.
Siegel RL, Miller KD, Jemal A (2016). Cancer statistics, 2016. CA Cancer J Clin, 66: 7-30.
Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. (2006). Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer, 95: 1314-20.
Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, et al. (2015). Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol, 125: 1345-52.
Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Allemani C, et al. (2009). The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer, 45:1006-16.
Janda M, Youlden DR, Baade PD, Jackson D, Obermair A. (2008). Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer, 18: 896-907.
Suidan RS, Leitao MMJr, Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, et al. (2015). Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol, 138: 246-51.
Sperling C, Noer MC, Christensen IJ, Nielsen ML, Lidegaard Ø, Høgdall C (2013). Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecol Oncol, 129: 97-102.
Colloca G, Santoro M, Gambassi G (2010). Age-related physiologic changes and perioperative management of elderly patients. Surgical oncology, 19(3):124-30.
Rodríguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W, et al. (2013). Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci, 68: 62-7.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. (2013). Frailty in elderly people. Lancet, 381:752-62.
Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. (2015). The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol, 26: 1091-101.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. (2001). Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci, 56: M146-56.
Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, et al. (2012). Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol, 126: 20-4.
Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. (2011). Gait speed and survival in older adults. JAMA, 305: 50-8.
Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney , et al.(2003). Physical performance measures in the clinical setting. J Am Geriatr Soc, 51: 314-22.
Pamoukdjian F, Paillaud E, Zelek L, Laurent M, Lévy V, Landre T, et al. (2015). Measurement of gait speed in older adults to identify complications associated with frailty: A systematic review. J Geriatr Oncol, 6: 484-96.
Verweij NM, Schiphorst AH, Pronk A, van den Bos F, Hamaker ME (2016). Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol, 8:1-6.
Cesari M, Cerullo F, Zamboni V, Di Palma R, Scambia G, Balducci L, et al. (2013). Functional status and mortality in older women with gynecological cancer. J Gerontol A Biol Sci Med Sci, 68: 1129-33.
Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E (2014). Sarcopenia and Physical Frailty: Two Sides of the Same Coin Front Aging Neurosci, 6: 192.
Rier HN, Jager A, Sleijfer S, Maier AB, Levin MD (2016). The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist, pii: theoncologist, 2016-0066.
Kumar A, Moynagh MR, Multinu F, Cliby WA, McGree ME, Weaver AL, et al. (2016). Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol, 142: 311-6.
Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T (2016). Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle, 7: 458-66.
Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. (2005). Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol, 55: 241-52.
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. (2014). International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol, 32: 2595-603.
PACE participants, Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, West C, et al. (2008). Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol, 65:156-63.
Tew WP (2016). Ovarian cancer in the older woman. J Geriatr Oncol, 7:354-61.
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. (2011). Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol, 29: 3457-65.
Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, et al. (2013). Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol, 24: 2808-13.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20: 1248-59.
Langstraat C, Aletti GD, Cliby WA (2011). Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol, 123: 187-91
Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. (2011). Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol, 120: 23-8.
Wright JD, Herzog TJ, Powell MA (2004). Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol, 190: 1398-400.
Fanfani F, Fagotti A, Salerno MG, Margariti PA, Gagliardi ML, Gallotta V, et al. (2012). Elderly and very elderly advanced ovarian cancer patients: does the age influence the surgical management? Eur J Surg Oncol. 38:1204-10.
Sharma S, Driscoll D, Odunsi K, Venkatadri A, Lele S (2005). Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol, 193:2077-82.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med, 363: 943-53.
Wright JD, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, et al. (2014). Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer, 120: 1246-54.
Joseph N, Clark RM, Dizon DS, Lee MS4, Goodman A, Boruta DJr, et al. (2015). Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol, 137: 401-405
Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, et al. (2008). Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol, 109: 33-38.
Hilpert F, du Bois A, Greimel ER, Hedderich J, Krause G, Venhoff L, et al. (2007). Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer-a study by the AGO OVAR Germany. Ann Oncol, 18: 282-287.
Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, et al. (2008). A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol, 66: 229-236.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. (2014). Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol, 15: 396-405.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 365: 2473-2483.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol, 30: 2039-2045.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. (2014). Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol, 32: 1302-1308.
Beinse G, Emile G, Cessot A, Boudou-Rouquette P, Huillard O, Saidu NE, et al. (2016). A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. Int J Gynecol Cancer, 26: 1196-1200.
Mustea Aet al. (2016). Impact of age on the safety and efficacy of bevacizumab-containing therapy in patients with primary ovarian cancer: Analyses of the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Working Group. Ann Oncol, 27(suppl_6): 867
Eccles DM, Balmaña J, Clune J, Ehlken B, Gohlke A, Hirst C, et al. (2016). Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review. Adv Ther, 33:129-150.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med, 366:1382-92.
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Coukos G (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348: 203-13.
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Fujii S (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A, 104: 3360-5.
Webb JR, Milne K, Kroeger DR, Nelson BH (2016). PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol, 141(2):293-302.
Gaillard SL, Secord AA, Monk B (2016). The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract, 3:11.
Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN (2016). Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs, 8(8):1437-1455.
Helissey C, Vicier C, Champiat S (2016). The development of immunotherapy in older adults: New treatments, new toxicities? J Geriatr Oncol, 7:325-33.
Oh J, Barve M, Matthews CM, et al. (2016). Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol, 504-510.